Mitochondria-targeted coenzyme Q10 nanocarriers evaluated by particle size and lipid composition alleviate early acetaminophen-induced liver injury

Key Points

• Acetaminophen-induced liver injury is alleviated by coenzyme Q10 nanocarriers, improving liver function.
• Key evidence includes significant reductions in injury markers after treatment with targeted therapy.
• Assessment using particle size and lipid composition of nanocarriers demonstrates their efficacy in therapeutic applications.
• Findings suggest that optimizing nanocarrier design may enhance treatments for liver injuries caused by acetaminophen.